<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03315520</url>
  </required_header>
  <id_info>
    <org_study_id>BeEAC-1</org_study_id>
    <nct_id>NCT03315520</nct_id>
  </id_info>
  <brief_title>BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation</brief_title>
  <acronym>BeEAC-1</acronym>
  <official_title>A Phase II, Multicenter, Prospective, Non-randomised, Open-label, Clinical Trial to Evaluate Effectiveness and Safety of BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nowadays there is no randomized trials for comparison the effectiveness and tolerability of
      different conditioning regimens.

      Bendamustine is a unique chemotherapeutic agent that combines alkylating action of nitrogen
      mustard and the activity of purine antimetabolite. Bendamustine has shown its effectiveness
      for the treatment of patients with chronic lymphoproliferative diseases such as chronic
      lymphocytic leukemia and several indolent lymphomas. The literature also presents evidence of
      the effectiveness bendamustine in patients with Hodgkin's lymphoma who received multiple
      lines of prior chemotherapy, including high dose chemotherapy and transplantation of
      peripheral hematopoietic stem cells. There are also data of using bendamustine as a part of
      conditioning regimen.

      In this context, it was planned a study for evaluation the safety and effectiveness of the
      BeEAC (bendamustine, etoposide, cytarabine, cyclophosphamide) conditioning regimen prior to
      autologous transplantation of peripheral hematopoietic stem cells for the treatment of
      relapsed/refractory malignant lymphomas.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>From admission till discharge from the hospital (approximately 30 days)</time_frame>
    <description>The primary safety analysis will be based on subjects who experienced toxicities as defined by CTCAE criteria. Safety will be assessed by quantifying the toxicities and grades experienced by subjects who have received BeEAC including serious adverse events (SAEs).
Adverse experiences will be graded and recorded throughout the study and during the follow-up period according to NCI CTCAE 4.03. Toxicities will be characterized in terms regarding seriousness, causality, toxicity grading and action taking with regard to trial treatment (Incidence of Treatment-Emergent Adverse Events).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective Comparison of Overall Survival between Carmustine, Etoposide, Cytarabine, Melphalan (BEAM), Cyclophosphamide, Carmustine, Etoposide(CBV) and BeEAC conditioning regimens</measure>
    <time_frame>2 years</time_frame>
    <description>The analysis will be based on comparison of overall survival between different conditioning regimens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Retrospective Comparison of Progression-Free Survival between Carmustine, Etoposide, Cytarabine, Melphalan (BEAM), Cyclophosphamide, Carmustine, Etoposide(CBV) and BeEAC conditioning regimens</measure>
    <time_frame>2 years</time_frame>
    <description>The analysis will be based on comparison of Progression-Free survival between different conditioning regimens</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Relapsed/Refractory Malignant Lymphomas</condition>
  <arm_group>
    <arm_group_label>Relapsed/refractory malignant lymphomas</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation using BeEAC (Bendamustine, Cytarabine, Etoposide, Cyclophosphamide) conditioning regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>BeEAC conditioning regimen:
bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)</description>
    <arm_group_label>Relapsed/refractory malignant lymphomas</arm_group_label>
    <other_name>Cytarabine</other_name>
    <other_name>Etoposide</other_name>
    <other_name>Cyclophosphamide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Be willing and able to provide written informed consent for the trial

          2. Be ≥ 18 years of age on day of signing informed consent

          3. Eastern Cooperative Oncology Group (ECOG) &lt; 2.

          4. Relapsed/refractory malignant lymphoma patients with indications to autologous
             hematopoietic stem-cell transplantation

        Exclusion Criteria:

          1. Participation in another clinical trials

          2. Clinically relevant heart disease:

               -  Myocardial infarction during previous 6 months

               -  Unstable angina during previous 3 months

               -  Congestive heart failure (III-IV NYHA)

               -  Clinically relevant ventricular arrhythmias

               -  corrected QT interval (QTc) &gt; 460 мс on ECG (calculated using Frederics formula)

               -  Left ventricular ejection fraction ≤ 45% on Echocardiogram

               -  Atrial Hypotension (systolic pressure &lt; 86 mmHg) or bradycardia (&lt; 50 per minute,
                  exclusion - drug-induced bradycardia)

               -  Uncontrolled arterial hypertension (systolic pressure &gt; 170 mmHg or diastolic
                  pressure &gt; 105 mmHg)

          3. Severe renal dysfunction (serum creatinine &gt; 250 µmol/l)

          4. Severe hepatic dysfunction (total bilirubin &gt; 40 µmol/l)

          5. Known history of Human Immunodeficiency Virus or active Hepatitis B and C

          6. Psychiatric or substance abuse disorders that would interfere with the cooperation
             with the requirements of the trial

          7. Hypersensitivity to investigational drugs

          8. Pregnant or breastfeeding females or males and females with childbearing potential
             must be willing to use an adequate method of birth control (intrauterine device,
             vasectomy of female subjects' male partner, contraceptive rod implanted into the skin,
             combination method - (requires use of two of the following) diaphragm with spermicide,
             cervical cap spermicide, contraceptive sponge, condom, hormonal contraceptive)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladislav Sarzhevskiy, MD, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Vladislav Sarzhevskiy, MD, PhD</last_name>
    <phone>+74956037217</phone>
    <email>vladsar100@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikita Mochkin, MD, PhD</last_name>
    <phone>+74956037217</phone>
    <email>nickmed@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladislav Sarzhevskiy, MD, PhD</last_name>
      <phone>+74956037217</phone>
      <email>vladsar100@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nikita Mochkin, MD, PhD</last_name>
      <phone>+74956037217</phone>
      <email>nickmed@yandex.ru</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <reference>
    <citation>Martino M, Olivieri A, Offidani M, Vigna E, Moscato T, Fedele R, Montanari M, Console G, Gentile M, Messina G, Irrera G, Morabito F. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma. Expert Opin Investig Drugs. 2013 May;22(5):619-34. doi: 10.1517/13543784.2013.788643. Epub 2013 Apr 4. Review.</citation>
    <PMID>23550793</PMID>
  </reference>
  <reference>
    <citation>Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, Boissevain F, Zschaber R, Müller P, Kirchner H, Lohri A, Decker S, Koch B, Hasenclever D, Goldstone AH, Diehl V; German Hodgkin's Lymphoma Study Group; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002 Jun 15;359(9323):2065-71.</citation>
    <PMID>12086759</PMID>
  </reference>
  <reference>
    <citation>Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, Hagenbeek A, Somers R, Chauvin F, Philip T. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood. 1998 Nov 15;92(10):3562-8.</citation>
    <PMID>9808548</PMID>
  </reference>
  <reference>
    <citation>Chen YB, Lane AA, Logan B, Zhu X, Akpek G, Aljurf M, Artz A, Bredeson CN, Cooke KR, Ho VT, Lazarus HM, Olsson R, Saber W, McCarthy P, Pasquini MC. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-1053. doi: 10.1016/j.bbmt.2015.02.005. Epub 2015 Feb 14.</citation>
    <PMID>25687795</PMID>
  </reference>
  <reference>
    <citation>Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol. 2008 Jan 10;26(2):204-10. doi: 10.1200/JCO.2007.12.5070. Erratum in: J Clin Oncol. 2008 Apr 10;26(11) 1911.</citation>
    <PMID>18182663</PMID>
  </reference>
  <reference>
    <citation>Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Merkle K, Montillo M. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol. 2012 Oct;159(1):67-77. doi: 10.1111/bjh.12000. Epub 2012 Aug 4.</citation>
    <PMID>22861163</PMID>
  </reference>
  <reference>
    <citation>Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH. Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. J Clin Oncol. 2013 Feb 1;31(4):456-60. doi: 10.1200/JCO.2012.45.3308. Epub 2012 Dec 17.</citation>
    <PMID>23248254</PMID>
  </reference>
  <reference>
    <citation>Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, Specchia G, Meloni G, Gherlinzoni F, Giardini C, Falcioni S, Cuberli F, Gobbi M, Sarina B, Santoro A, Ferrara F, Rocchi M, Ocio EM, Caballero MD, Isidori A. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011 Sep 22;118(12):3419-25. doi: 10.1182/blood-2011-04-351924. Epub 2011 Aug 3.</citation>
    <PMID>21816830</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2017</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hodgkin Lymphoma</keyword>
  <keyword>Non-Hodgkin lymphoma</keyword>
  <keyword>autologous hematopoietic stem-cell transplantation</keyword>
  <keyword>conditioning regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

